NU Hospitals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: NU Hospitals Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $1.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

NU Hospitals Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $1.0M Trade | TransData Nexus

NU Hospitals Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $1.0M Total Trade · DGFT Verified

NU Hospitals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.0M across 7 products in 3 therapeutic categories. Based on 115 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Trastuzumab ($673.7K), Osimertinib ($130.8K), Pembrolizumab ($130.1K).

NU Hospitals Private Limited — Export Portfolio & Destination Treemap

NU Hospitals Private Limited pharmaceutical export portfolio — 7 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is NU Hospitals Private Limited? — Company Overview & Market Position

NU Hospitals Private Limited, established on April 10, 2006, is a private, non-governmental company headquartered in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U85120KA2006PTC038963. As of the latest available data, NU Hospitals has an authorized share capital of ₹100 million and a paid-up capital of ₹89.49 million. The company specializes in healthcare services, focusing on nephrology, urology, and fertility treatments.

The registered office is located at C.A. 6, 15th Main, 11th Cross, Padmanabhanagar, Bangalore, Karnataka 560070, India. The company employs approximately 405 individuals as of April 5, 2024. NU Hospitals operates a network of facilities, including locations in Bangalore, Shivamogga, Ambur, and the Maldives, offering specialized services in nephrology, urology, and fertility treatments.

What Does NU Hospitals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Trastuzumab$673.7K 2

Product Portfolio — Top 7 by Export Value

NU Hospitals Private Limited exports 7 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Trastuzumab	Advanced Oncology	$673.7K	62	0.9%	9
2	Osimertinib	Advanced Oncology	$130.8K	4	12.0%	2
3	Pembrolizumab	Advanced Oncology	$130.1K	30	6.7%	8
4	Nicotine	Other	$36.1K	5	0.2%	8
5	Cetuximab	Advanced Oncology	$34.5K	6	4.1%	5
6	Nivolumab	Advanced Oncology	$12.0K	5	0.5%	10
7	Soframycin	Brand Names & OTC Products	$1.1K	3	0.2%	5

NU Hospitals Private Limited exports 7 pharmaceutical products across 3 therapeutic categories with a total export value of $1.0M. The top category is Advanced Oncology (96.3% of portfolio), followed by Other (3.5%), indicating a concentrated portfolio with the top 5 products accounting for 98.7% of total export value.

NU Hospitals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

NU Hospitals Private Limited primarily focuses on healthcare services and does not operate manufacturing facilities for pharmaceutical products. The company's operations are centered around providing specialized medical treatments in nephrology, urology, and fertility through its network of hospitals and clinics.

3Key Leadership

The leadership team of NU Hospitals Private Limited includes:

Venkatesh Krishnamurthy – Founder and Managing Director.

Potineni Koteswara Rao – Director.

Selva Muthukumarasamy – Director.

Ramachandra Munisamappa – Director.

Mattipa Prasanna Venkatesh – Director.

Mattipa Ramasamy Kanthiraj – Director.

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does NU Hospitals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

NU Hospitals Private Limited's primary operations are within India, focusing on providing specialized healthcare services. The company does not have publicly available information regarding regulatory filings, approvals, or market access status in the United States, European Union, United Kingdom, Australia, or Japan. Therefore, an analysis of its presence in these regulated markets cannot be conducted based on the available data.

2Emerging Markets

NU Hospitals Private Limited has extended its services to the Maldives, operating facilities such as NU Hospitals in Malé and Hulhumalé. This expansion into the Maldives indicates the company's interest in emerging markets. However, there is no specific information available regarding WHO prequalification or other certifications that would enable access to additional emerging markets. Consequently, a detailed analysis of its presence in Africa, Latin America, or Southeast Asia cannot be provided based on the current data.

3Geographic Strategy

NU Hospitals Private Limited's geographic strategy appears to be focused on regional expansion within India and into neighboring countries like the Maldives. The company's operations in Bangalore, Shivamogga, Ambur, and the Maldives suggest a strategy aimed at serving both domestic and regional markets. However, without specific data on market diversification or concentration risks, a comprehensive assessment of its geographic diversification and strategic direction cannot be provided.

NU Hospitals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As NU Hospitals Private Limited specializes in healthcare services, particularly in nephrology, urology, and fertility treatments, it does not manufacture pharmaceutical products. Therefore, the company does not have FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history related to pharmaceutical manufacturing. Consequently, an analysis of its FDA status is not applicable.

2WHO & EU GMP

NU Hospitals Private Limited's operations are centered around providing specialized medical treatments and do not involve the manufacturing of pharmaceutical products. Therefore, the company does not hold WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. An assessment of its compliance with these standards is not applicable.

3CDSCO & Indian Regulatory

As a healthcare service provider, NU Hospitals Private Limited operates under the regulatory framework established by the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers in India. The company holds the necessary licenses and approvals to provide medical services in its operating regions. However, specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available. Therefore, a detailed analysis of its compliance with Indian regulatory requirements cannot be conducted based on the available data.

NU Hospitals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the specialized fields of nephrology, urology, and fertility treatments, NU Hospitals Private Limited faces competition from other healthcare providers in India and the Maldives. However, specific data regarding market share comparisons, head-to-head analyses, or detailed competitor information are not available. Consequently, a comprehensive competitive landscape analysis cannot be provided based on the current data.

2Key Differentiators

NU Hospitals Private Limited differentiates itself through its specialized focus on nephrology, urology, and fertility treatments. The company has been a pioneer in these fields, being one of the first in Karnataka to conduct successful kidney transplantation surgeries and to equip its urology department with advanced flexible endoscopes. Additionally, the establishment of a dedicated Men's Health Clinic addresses sexual and reproductive health, further distinguishing the hospital's service offerings.

3Strategic Position

NU Hospitals Private Limited's strategic direction centers on providing specialized healthcare services in nephrology, urology, and fertility treatments. The company's focus on advanced medical services and continuous learning positions it as a leader in these specialized fields. Future outlooks include expanding service offerings and exploring new markets to increase access to healthcare services for both domestic and international patients.

Buyer Due Diligence Brief — Evaluating NU Hospitals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

As NU Hospitals Private Limited does not engage in the manufacturing of pharmaceutical products, it does not function as a supplier in the pharmaceutical industry. Therefore, an assessment of its track record, export volume, consistency, or reliability indicators in this context is not applicable.

2Certifications to Verify

For healthcare service providers like NU Hospitals Private Limited, importers and partners should verify the following certifications:

FDA Registration: To ensure compliance with U.S. healthcare standards. Verification can be done through the FDA's official database.

WHO-GMP Certification: To confirm adherence to World Health Organization's Good Manufacturing Practices. Verification can be conducted via the WHO's official website.

EU GMP Certification: To ensure compliance with European Union's Good Manufacturing Practices. Verification can be performed through the European Medicines Agency (EMA).

Frequently Asked Questions — NU Hospitals Private Limited

How many pharmaceutical products does NU Hospitals Private Limited export from India?

NU Hospitals Private Limited exports 7 pharmaceutical products across 3 therapeutic categories. The top exports are Trastuzumab ($673.7K), Osimertinib ($130.8K), Pembrolizumab ($130.1K), Nicotine ($36.1K), Cetuximab ($34.5K). Total export value is $1.0M.

What is NU Hospitals Private Limited's total pharmaceutical export value?

NU Hospitals Private Limited's total pharmaceutical export value is $1.0M, based on 115 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does NU Hospitals Private Limited cover?

NU Hospitals Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (96.3%, 5 products), Other (3.5%, 1 products), Brand Names & OTC Products (0.1%, 1 products).

Get Full NU Hospitals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.